Nitrazepam Accord

Nitrazepam, the active ingredient in Nitrazepam Accord, is a benzodiazepine presented as an oral tablet for oral use. It is employed to manage insomnia, anxiety disorders, and certain seizure types, primarily in adult patients requiring short‑term therapeutic intervention.

GNH USA supplies Nitrazepam Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution. Clients benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Nitrazepam acts on the central nervous system as a sedative‑hypnotic, addressing several disorders that involve excessive neuronal excitability.

- Insomnia: helps initiate and maintain sleep in patients with difficulty falling asleep or experiencing frequent nocturnal awakenings, and improves daytime functioning. - Anxiety disorders: reduces excessive nervous tension, restlessness and associated physiological symptoms in generalized anxiety and related conditions, and promotes a calmer mental state. - Seizure disorders: provides adjunctive control of certain focal and generalized seizure types, improving overall seizure frequency when used as prescribed, and may reduce the need for additional rescue medication.

Nitrazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Fatigue: general lack of energy and motivation. - Impaired coordination: clumsiness or difficulty with fine motor tasks. - Memory disturbances: short‑term recall problems. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with high doses or other depressants. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Depression or suicidal thoughts: mood changes requiring immediate medical attention. - Withdrawal syndrome: rebound anxiety, insomnia, or seizures after abrupt discontinuation. - Psychomotor impairment: slowed reaction time affecting driving or operating machinery. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing nitrazepam, clinicians should consider several safety precautions to minimize risks.

- Assess patient history: evaluate for prior substance abuse, respiratory disorders, or hepatic impairment. - Limit duration: use the lowest effective dose for the shortest period to reduce dependence risk. - Avoid abrupt cessation: taper the dose gradually under medical supervision to prevent withdrawal. - Caution in elderly: increased sensitivity to sedation and falls; start at lower doses. - Pregnancy and lactation: contraindicated in pregnancy (Category D) and not recommended while breastfeeding. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nitrazepam can interact with other medicines, altering its effects or increasing adverse reactions.

Major Interactions (Avoid): - CNS depressants: concurrent use with opioids, barbiturates, or alcohol may cause profound sedation or respiratory depression. - Antifungal azoles: agents such as ketoconazole can increase nitrazepam plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Antidepressants: selective serotonin reuptake inhibitors may enhance sedative effects. - Anticonvulsants: enzyme inducers like carbamazepine may reduce nitrazepam efficacy. - Antihistamines: first‑generation antihistamines can add to drowsiness. - Oral contraceptives: may slightly increase nitrazepam concentrations.